Pioneering novel clinical protocols and targeted therapies for cancer and neurodegenerative disorders
Our mission is to expedite the development of immuno-therapy technologies for cancer, neurodegenerative disorders, and other unmet medical needs.
In 2024, ~10 million cancer deaths were reported worldwide, with 21 million newly diagnosed cancer patients. Metastasis—the spread of cancer to other organs usually via the blood or lymph—remains the primary cause of cancer-related deaths, often occurring after initial treatments like chemotherapy, radiation, or surgery have failed to eliminate every cancer cell. Once standard therapies have failed and cancer has metastasized, the management of the disease shifts significantly.
According to the World Health Organization, more than 3 billion people lived with a neurological condition worldwide in 2021, and there are currently more than 55 million people living with dementia. Alzheimer's disease is the 6th leading cause of death in the U.S., and nearly 1 million Americans live with Parkinson's disease.
Our Leadership
Sant P. Chawla, MD
Chair / CEO / DirectorDirector of Cancer Center of Southern California, providing multi-disciplinary, experimental, and advanced cancer care
Erlinda M. Gordon, MD
Vice-Chair / CFO / DirectorDirector of Gene and Cell Therapy Division of Cancer Center of Southern California and President of Aveni Foundation
Ania Moradkhani, NP
Secretary / DirectorNurse Practitioner at Cancer Center of Southern California
Contact us
To donate, make checks payable to Innovative Immuno-oncology Consortium:
2811 Wilshire Blvd, STE 420, Santa Monica, CA 90403
outreach@iioncology.org
Wire transfer information available upon request